Evidence map›Paper›PMID 32357967›Full record

ArticleCancer discovery2020

Trying for a BRAF Slam Dunk.

Antoni Ribas, Roger S Lo

Abstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer discovery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Antoni RibasJonsson Comprehensive Cancer Center at the University of California, Los Angeles, Los Angeles, California. aribas@mednet.ucla.edu rlo@mednet.ucla.edu.
Roger S LoJonsson Comprehensive Cancer Center at the University of California, Los Angeles, Los Angeles, California. aribas@mednet.ucla.edu rlo@mednet.ucla.edu.

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
Transductionally Redirected /Transcriptionally RestricteP50CA086306 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HERSCHMAN, HARVEY R. · 2000 to 2014
$29.0M
Project 3: Modeling and overcoming resistance to melanoma immunotherapyP01CA244118 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RIBAS, ANTONI · 2020 to 2024
$12.8M
Repurposing of cancer therapeutics for treatment of patients with COVID-19 diseaseU54CA199090 · NCI · INSTITUTE FOR SYSTEMS BIOLOGY · PI HEATH, JAMES R., RIBAS, ANTONI · 2015 to 2020
$11.4M
Next Generation Cancer Immunotherapies to Defeat MelanomaR35CA197633 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANTONI RIBAS · 2015 to 2026
$10.4M
TARGETED COMBINATORIAL TREATMENT OF BRAF MELANOMASP01CA168585 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TSENG, HSIAN-RONG · 2013 to 2017
$8.4M
Preventing MAPK inhibitor resistance in melanoma by targeting genomic instability and immune resistanceR01CA176111 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ROGER S LO · 2013 to 2026
$5.4M
Strategies for Distinguishing Success in Immunotherapy Treatments (PQ20)R01CA170689 · NCI · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI HEATH, JAMES R., RIBAS, ANTONI · 2012 to 2015
$2.5M
Augmenting Melanoma Response to B-Raf V600E TargetingK22CA151638 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LO, ROGER S · 2010 to 2012
$561k
Exploiting Drug Addiction to Improve the Efficacy of MAPK Pathway Targeted Therapy in BRAF and NRAS Mutant MelanomaR21CA215910 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LO, ROGER S · 2018 to 2019
$367k
NCI NIH HHS K22 CA151638NCI NIH HHS P01 CA168585NCI NIH HHS P01 CA244118NCI NIH HHS P30 CA016042NCI NIH HHS P50 CA086306NCI NIH HHS R01 CA170689NCI NIH HHS R01 CA176111NCI NIH HHS R21 CA215910NCI NIH HHS R35 CA197633NCI NIH HHS U54 CA199090
6 · The paper itself

Abstract

The first basket clinical trial testing the BRAF inhibitor vemurafenib resulted in evidence of activity in 13 unique cancer types with

Indexed as

NeoplasmsProto-Oncogene Proteins B-rafHumansMutationProtein Kinase InhibitorsVemurafenibBRAF protein, humanProtein Kinase InhibitorsProto-Oncogene Proteins B-rafVemurafenib

Identifiers

PMID32357967
PMCPMC7363198

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.